BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97. [PMID: 24400774 DOI: 10.1517/14728214.2014.875529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Störmann S, Schopohl J. Drug treatment strategies for secondary diabetes in patients with acromegaly. Expert Opin Pharmacother 2020;21:1883-95. [PMID: 32633582 DOI: 10.1080/14656566.2020.1789098] [Reference Citation Analysis]
2 Lan H, Li W, Li R, Zheng X, Luo G. Endocytosis and Degradation of Pegvisomant and a Potential New Mechanism That Inhibits the Nuclear Translocation of GHR. J Clin Endocrinol Metab 2019;104:1887-99. [PMID: 30602026 DOI: 10.1210/jc.2018-02063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Paragliola RM, Salvatori R. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Front Endocrinol (Lausanne) 2018;9:78. [PMID: 29563895 DOI: 10.3389/fendo.2018.00078] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
4 Störmann S, Schopohl J. Perspectives on investigational drugs for acromegaly. Expert Opinion on Investigational Drugs 2016;25:381-4. [DOI: 10.1517/13543784.2016.1142530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol 2016;12:90-8. [PMID: 26610414 DOI: 10.1038/nrendo.2015.196] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
6 Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 2016;10:227-39. [PMID: 26811671 DOI: 10.2147/DDDT.S77999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
7 Plunkett C, Barkan AL. The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence. 2015;9:1093-1099. [PMID: 26251582 DOI: 10.2147/ppa.s84887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
8 Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opinion on Investigational Drugs 2014;23:1619-35. [DOI: 10.1517/13543784.2014.942728] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]